This page has only limited features, please log in for full access.
SARS-CoV-2 is the causative agent of COVID-19, which is a global pandemic. SARS-CoV-2 is transmitted rapidly via contaminated surfaces and aerosols, emphasizing the importance of environmental disinfection to block the spread of virus. Ultraviolet C radiation and chemical compounds are effective for SARS-CoV-2 disinfection, but can only be applied in the absence of humans due to their toxicities. Therefore, development of disinfectants that can be applied in working spaces without evacuating people is needed. Here we showed that TiO2-mediated photocatalytic reaction inactivates SARS-CoV-2 in a time-dependent manner and decreases its infectivity by 99.9% after 20 min and 120 min of treatment in aerosol and liquid, respectively. The mechanistic effects of TiO2 photocatalyst on SARS-CoV-2 virion included decreased total observed virion count, increased virion size, and reduced particle surface spike structure, as determined by transmission electron microscopy. Damage to viral proteins and genome was further confirmed by western blotting and RT-qPCR, respectively. The multi-antiviral effects of TiO2-mediated photocatalytic reaction implies universal disinfection potential for different infectious agents. Notably, TiO2 has no adverse effects on human health, and therefore, TiO2-induced photocatalytic reaction is suitable for disinfection of SARS-CoV-2 and other emerging infectious disease-causing agents in human habitation.
Ryosuke Matsuura; Chieh-Wen Lo; Satoshi Wada; Junichi Somei; Heihachiro Ochiai; Takeharu Murakami; Norihito Saito; Takayo Ogawa; Atsushi Shinjo; Yoshimi Benno; Masaru Nakagawa; Masami Takei; Yoko Aida. SARS-CoV-2 Disinfection of Air and Surface Contamination by TiO2 Photocatalyst-Mediated Damage to Viral Morphology, RNA, and Protein. Viruses 2021, 13, 942 .
AMA StyleRyosuke Matsuura, Chieh-Wen Lo, Satoshi Wada, Junichi Somei, Heihachiro Ochiai, Takeharu Murakami, Norihito Saito, Takayo Ogawa, Atsushi Shinjo, Yoshimi Benno, Masaru Nakagawa, Masami Takei, Yoko Aida. SARS-CoV-2 Disinfection of Air and Surface Contamination by TiO2 Photocatalyst-Mediated Damage to Viral Morphology, RNA, and Protein. Viruses. 2021; 13 (5):942.
Chicago/Turabian StyleRyosuke Matsuura; Chieh-Wen Lo; Satoshi Wada; Junichi Somei; Heihachiro Ochiai; Takeharu Murakami; Norihito Saito; Takayo Ogawa; Atsushi Shinjo; Yoshimi Benno; Masaru Nakagawa; Masami Takei; Yoko Aida. 2021. "SARS-CoV-2 Disinfection of Air and Surface Contamination by TiO2 Photocatalyst-Mediated Damage to Viral Morphology, RNA, and Protein." Viruses 13, no. 5: 942.
Many human viruses, including Epstein-Barr virus (EBV), do not infect mice, which is challenging for biomedical research. We have previously reported that EBV infection induces erosive arthritis, which histologically resembles rheumatoid arthritis, in humanized NOD/Shi-scid/IL-2Rγ null (hu-NOG) mice; however, the underlying mechanisms are not known. Osteoclast-like multinucleated cells were observed during bone erosion in this mouse model, and therefore, we aimed to determine whether the human or mouse immune system activated bone erosion and analyzed the characteristics and origin of the multinucleated cells in hu-NOG mice. Sections of the mice knee joint tissues were immunostained with anti-human antibodies against certain osteoclast markers, including cathepsin K and matrix metalloproteinase-9 (MMP-9). Multinucleated cells observed during bone erosion stained positively for human cathepsin K and MMP-9. These results indicate that human osteoclasts primarily induce erosive arthritis during EBV infections. Human osteoclast development from hematopoietic stem cells transplanted in hu-NOG mice remains unclear. To confirm their differentiation potential into human osteoclasts, we cultured bone marrow cells of EBV-infected hu-NOG mice and analyzed their characteristics. Multinucleated cells cultured from the bone marrow cells stained positive for human cathepsin K and human MMP-9, indicating that bone marrow cells of hu-NOG mice could differentiate from human osteoclast progenitor cells into human osteoclasts. These results indicate that the human immune response to EBV infection may induce human osteoclast activation and cause erosive arthritis in this mouse model. Moreover, this study is the first, to our knowledge, to demonstrate human osteoclastogenesis in humanized mice. We consider that this model is useful for studying associations of EBV infections with rheumatoid arthritis and human bone metabolism.
Yosuke Nagasawa; Masami Takei; Mitsuhiro Iwata; Yasuko Nagatsuka; Hiroshi Tsuzuki; Kenichi Imai; Ken-Ichi Imadome; Shigeyoshi Fujiwara; Noboru Kitamura. Human osteoclastogenesis in Epstein-Barr virus-induced erosive arthritis in humanized NOD/Shi-scid/IL-2Rγnull mice. PLOS ONE 2021, 16, e0249340 .
AMA StyleYosuke Nagasawa, Masami Takei, Mitsuhiro Iwata, Yasuko Nagatsuka, Hiroshi Tsuzuki, Kenichi Imai, Ken-Ichi Imadome, Shigeyoshi Fujiwara, Noboru Kitamura. Human osteoclastogenesis in Epstein-Barr virus-induced erosive arthritis in humanized NOD/Shi-scid/IL-2Rγnull mice. PLOS ONE. 2021; 16 (4):e0249340.
Chicago/Turabian StyleYosuke Nagasawa; Masami Takei; Mitsuhiro Iwata; Yasuko Nagatsuka; Hiroshi Tsuzuki; Kenichi Imai; Ken-Ichi Imadome; Shigeyoshi Fujiwara; Noboru Kitamura. 2021. "Human osteoclastogenesis in Epstein-Barr virus-induced erosive arthritis in humanized NOD/Shi-scid/IL-2Rγnull mice." PLOS ONE 16, no. 4: e0249340.
Noboru Kitamura; Hitomi Kobayashi; Masami Takei; Yasuyuki Kobayashi. Unique cardiac magnetic resonance imaging findings of progressing myocardial damage in a patient with polymyositis. Archives of Rheumatology 2020, 36, 314 -315.
AMA StyleNoboru Kitamura, Hitomi Kobayashi, Masami Takei, Yasuyuki Kobayashi. Unique cardiac magnetic resonance imaging findings of progressing myocardial damage in a patient with polymyositis. Archives of Rheumatology. 2020; 36 (2):314-315.
Chicago/Turabian StyleNoboru Kitamura; Hitomi Kobayashi; Masami Takei; Yasuyuki Kobayashi. 2020. "Unique cardiac magnetic resonance imaging findings of progressing myocardial damage in a patient with polymyositis." Archives of Rheumatology 36, no. 2: 314-315.
Objective. The risk of clinically manifested major cardiovascular (CV) events in primary Sjögren syndrome (pSS) remains unclear. This study aimed to assess myocardial fibrosis in pSS and investigate the associated disease characteristics by cardiac magnetic resonance imaging (cMRI). Methods. We performed a cross-sectional study of patients with pSS without cardiac symptoms. Labial gland biopsy was documented in 44 patients (85%). Patients without CV risk factors underwent contrast-enhanced cMRI. Late gadolinium enhancement (LGE) was used to assess myocardial fibrosis. Myocardial edema was assessed using T2-weighted imaging (T2WI). We compared the left ventricular (LV) geometry and function between the groups with and without LGE. Further, we explored the associations of cMRI abnormalities with pSS characteristics. Results. Fifty-two women with pSS (median age 55, IQR 47.0–65.7 yrs) were enrolled in the study. LGE was observed in 10 patients (19%), two of whom showed high intensity on T2WI. High intensity on T2WI was observed in 3 patients (5.8%). LV mass index and LV mass/end-diastolic volume tended to be higher in the LGE-positive group than in the LGE-negative group (P = 0.078 and 0.093, respectively). Salivary gland focus score (FS) ≥ 3 was independently associated with LGE-positive in the multivariable analysis (OR 11.21, 95% CI 1.18–106.80). Conclusion. Subclinical myocardial fibrosis, as detected by cMRI, was frequent in patients with pSS without cardiac symptoms. Abnormal cMRI findings were associated with salivary gland FS ≥ 3.
Atsuma Nishiwaki; Hitomi Kobayashi; Natsumi Ikumi; Yasuyuki Kobayashi; Isamu Yokoe; Kaita Sugiyama; Yoshihiro Matsukawa; Masami Takei; Noboru Kitamura. Salivary Gland Focus Score Is Associated With Myocardial Fibrosis in Primary Sjögren Syndrome Assessed by a Cardiac Magnetic Resonance Approach. The Journal of Rheumatology 2020, 48, 859 -866.
AMA StyleAtsuma Nishiwaki, Hitomi Kobayashi, Natsumi Ikumi, Yasuyuki Kobayashi, Isamu Yokoe, Kaita Sugiyama, Yoshihiro Matsukawa, Masami Takei, Noboru Kitamura. Salivary Gland Focus Score Is Associated With Myocardial Fibrosis in Primary Sjögren Syndrome Assessed by a Cardiac Magnetic Resonance Approach. The Journal of Rheumatology. 2020; 48 (6):859-866.
Chicago/Turabian StyleAtsuma Nishiwaki; Hitomi Kobayashi; Natsumi Ikumi; Yasuyuki Kobayashi; Isamu Yokoe; Kaita Sugiyama; Yoshihiro Matsukawa; Masami Takei; Noboru Kitamura. 2020. "Salivary Gland Focus Score Is Associated With Myocardial Fibrosis in Primary Sjögren Syndrome Assessed by a Cardiac Magnetic Resonance Approach." The Journal of Rheumatology 48, no. 6: 859-866.
Aim To evaluate left ventricular (LV) dysfunction in patients with rheumatoid arthritis (RA) and to determine the impact of biological treatment on LV function in these patients using global circumferential strain (GCS), global longitudinal strain (GLS) and global radial strain (GRS) values assessed by feature tracking cardiac magnetic resonance (FT‐CMR) imaging. Methods Eighty patients with RA and 20 controls without cardiovascular disease underwent non‐contrast CMR imaging. Patients with RA received conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) or biologic DMARDs (bDMARDs). Global strains were calculated in 16 LV segments. Results No significant differences in cardiovascular risk factors were found between the RA group and controls. GCS was 21% lower in the RA group compared with controls (P < 0.001) and was 14% lower in the csDMARDs group compared with the bDMARDs group (P = 0.002), whereas, there was no significant difference in GLS and GRS between the RA group and the controls. In regard to strain rates, diastolic GCS and GRS rates were significantly lower in the RA group (P < 0.001, 0.011, respectively). In univariate analyses, GCS was significantly associated with the Simplified Disease Activity Index, bDMARDs, swollen joint count, anti‐cyclic citrullinated peptides antibodies and matrix metalloproteinase‐3, but in multivariable analysis, only bDMARDs was significantly associated with GCS (P = 0.021). Conclusion Global circumferential strain, GLS and GRS assessed by FT‐CMR can reveal subclinical LV dysfunction in patients with RA. Furthermore, they can be used to determine the normalization of LV regional dysfunction induced by bDMARDs possibly related to disease activity reduction.
Isamu Yokoe; Hitomi Kobayashi; Yasuyuki Kobayashi; Atsuma Nishiwaki; Kaita Sugiyama; Yousuke Nagasawa; Natsumi Ikumi; Hiromi Karasawa; Yasuo Okumura; Noboru Kitamura; Masami Takei. Impact of biological treatment on left ventricular dysfunction determined by global circumferential, longitudinal and radial strain values using cardiac magnetic resonance imaging in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases 2020, 1 .
AMA StyleIsamu Yokoe, Hitomi Kobayashi, Yasuyuki Kobayashi, Atsuma Nishiwaki, Kaita Sugiyama, Yousuke Nagasawa, Natsumi Ikumi, Hiromi Karasawa, Yasuo Okumura, Noboru Kitamura, Masami Takei. Impact of biological treatment on left ventricular dysfunction determined by global circumferential, longitudinal and radial strain values using cardiac magnetic resonance imaging in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases. 2020; ():1.
Chicago/Turabian StyleIsamu Yokoe; Hitomi Kobayashi; Yasuyuki Kobayashi; Atsuma Nishiwaki; Kaita Sugiyama; Yousuke Nagasawa; Natsumi Ikumi; Hiromi Karasawa; Yasuo Okumura; Noboru Kitamura; Masami Takei. 2020. "Impact of biological treatment on left ventricular dysfunction determined by global circumferential, longitudinal and radial strain values using cardiac magnetic resonance imaging in patients with rheumatoid arthritis." International Journal of Rheumatic Diseases , no. : 1.
Current therapies for human immunodeficiency virus type 1 (HIV-1) do not completely eliminate viral reservoirs in cells, such as macrophages. The HIV-1 accessory protein viral protein R (Vpr) promotes virus production in macrophages, and the maintenance of Vpr is essential for HIV-1 replication in these reservoir cells. We identified two novel Vpr-binding proteins, i.e., protein arginine N-methyltransferases (PRMTs) 5 and 7, using human monocyte-derived macrophages (MDMs). Both proteins found to be important for prevention of Vpr degradation by the proteasome; in the context of PRMT5 and PRMT7 knockdowns, degradation of Vpr could be prevented using a proteasome inhibitor. In MDMs infected with a wild-type strain, knockdown of PRMT5/PRMT7 and low expression of PRMT5 resulted in inefficient virus production like Vpr-deficient strain infections. Thus, our findings suggest that PRMT5 and PRMT7 support HIV-1 replication via maintenance of Vpr protein stability.
Hironobu Murakami; Takehiro Suzuki; Kiyoto Tsuchiya; Hiroyuki Gatanaga; Manabu Taura; Eriko Kudo; Seiji Okada; Masami Takei; Kazumichi Kuroda; Tatsuo Yamamoto; Kyoji Hagiwara; Naoshi Dohmae; Yoko Aida. Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production. Viruses 2020, 12, 355 .
AMA StyleHironobu Murakami, Takehiro Suzuki, Kiyoto Tsuchiya, Hiroyuki Gatanaga, Manabu Taura, Eriko Kudo, Seiji Okada, Masami Takei, Kazumichi Kuroda, Tatsuo Yamamoto, Kyoji Hagiwara, Naoshi Dohmae, Yoko Aida. Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production. Viruses. 2020; 12 (3):355.
Chicago/Turabian StyleHironobu Murakami; Takehiro Suzuki; Kiyoto Tsuchiya; Hiroyuki Gatanaga; Manabu Taura; Eriko Kudo; Seiji Okada; Masami Takei; Kazumichi Kuroda; Tatsuo Yamamoto; Kyoji Hagiwara; Naoshi Dohmae; Yoko Aida. 2020. "Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production." Viruses 12, no. 3: 355.
The D-type cyclin (CCND)-cyclin-dependent kinase 4/6 (CDK4/6) complex has been implicated in multiple myeloma development. We investigated the biological activity of CDK4/6 inhibitor abemaciclib on cell growth and survival in three myeloma cell lines, KMS-12-PE, RPMI 8226, and IM-9. Abemaciclib inhibited myeloma cell growth in a dose-dependent manner in all cell lines, with significant differences seen at a concentration of 320 nM. Treatment with 1 μM abemaciclib increased the fraction of cells in the G0/G1 phase and decreased the fraction in the S-G2/M phases. Further, treatment with abemaciclib at a concentration of 3.2 μM or more showed apparent cytocidal activity accompanied with cytoplasmic vacuolization against myeloma cells. Importantly, abemaciclib induced autophagy in a dose-dependent manner in all three cell lines. These results indicate that the CCND-CDK4/6 complex is closely tied to myeloma cell growth and survival.
Noriyoshi Iriyama; Hirotsugu Hino; Shota Moriya; Masaki Hiramoto; Yoshihiro Hatta; Masami Takei; Keisuke Miyazawa. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells. Leukemia & Lymphoma 2017, 59, 1439 -1450.
AMA StyleNoriyoshi Iriyama, Hirotsugu Hino, Shota Moriya, Masaki Hiramoto, Yoshihiro Hatta, Masami Takei, Keisuke Miyazawa. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells. Leukemia & Lymphoma. 2017; 59 (6):1439-1450.
Chicago/Turabian StyleNoriyoshi Iriyama; Hirotsugu Hino; Shota Moriya; Masaki Hiramoto; Yoshihiro Hatta; Masami Takei; Keisuke Miyazawa. 2017. "The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells." Leukemia & Lymphoma 59, no. 6: 1439-1450.
Lyn, an import member of Src family kinases (SFKs), is supposed to be implicated in acute myeloid leukemia (AML) pathogenesis and development by participation in AML differentiation, yet the details still remain incompletely understood. The expression status of Lyn and its correlation with multiple clinical parameters including cell differentiation degree, different cytogenetic risk classification, and the activity of myeloperoxidase (MPO) were thus investigated. To address the mechanisms underlying the involvement of Lyn in differentiation induction, the effects of dasatinib, an inhibitor for SFKs including Lyn, on the alterations of all-trans retinoic acid (ATRA)- or dihydroxyvitamin D3 (VD3)-induced differentiation, and c-Myc protein expression were investigated. Primary AML blasts were obtained from 31 newly diagnosed AML patients with different French-American-British (FAB) subtypes. The expression of phosphorylated and total Lyn, c-Myc, and CD11b, CD11c and CD15 was analyzed by flow cytometry. The activation of Akt and Erk known to be involved in the regulation of c-Myc expression was investigated using western blotting. Significant higher expression levels of total Lyn were observed in AML patients with favorable cytogenetics, higher MPO activity and FAB M2 subtype. A clear positive correlation between the expression levels of Lyn and differentiation status of primary AML blasts was observed. Dasatinib inhibited the expression of phosphorylated Lyn, and further enhanced the differentiation-inducing activity of ATRA and VD3 in HL-60 cells. Augmented downregulation of c-Myc protein expression was observed in the combination treatment with ATRA, VD3 and dasatinib compared to treatment with each reagent alone in HL-60 cells. The suppression of the activation of Akt and Erk was also observed concomitantly. The expression level of total Lyn is closely linked to the differentiation status of AML blasts. The enhancement of differentiation-inducing activity of ATRA/VD3 by dasatinib suggested that Lyn was associated in the negative regulation of ATRA/VD3-induced HL-60 cells differentiation. The enhancement probably was attributed to the downregulation of c-Myc implicated with the suppression of the activation of Akt and Erk. These results provide novel insights into a possible combinational therapeutic approach by targeting Lyn for AML patients, and offer new possibilities for the combination therapy with VD3 and dasatinib.
Noriyoshi Iriyama; Bo Yuan; Yoshihiro Hatta; Norio Takagi; Masami Takei. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. Cancer Cell International 2016, 16, 37 .
AMA StyleNoriyoshi Iriyama, Bo Yuan, Yoshihiro Hatta, Norio Takagi, Masami Takei. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. Cancer Cell International. 2016; 16 (1):37.
Chicago/Turabian StyleNoriyoshi Iriyama; Bo Yuan; Yoshihiro Hatta; Norio Takagi; Masami Takei. 2016. "Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation." Cancer Cell International 16, no. 1: 37.
Co-expression of MYC and BCL2 proteins in diffuse large B-cell lymphoma (DLBCL), or 'double-expressor lymphoma' (DEL), results in poor patient prognosis, but the significance of DEL when aggressive treatments are applied remains uncertain. We performed a retrospective analysis of 40 patients with de novo DLBCL, who were categorized as being at high/high-intermediate risk according to the age-adjusted International Prognostic Index. Patients underwent an R-Double-CHOP regimen, a dose-intensified immunochemotherapy with or without consolidative high-dose chemotherapy followed by autologous stem cell transplantation. According to immunohistochemical analysis, 10 (25%) patients were categorized as having DEL, showing positivity for MYC (≥40%) and BCL2 (≥50%). The 3 year progression-free survival and overall survival of the DEL group were significantly worse compared with those of the non-DEL group (30% vs. 63%, p = 0.019 and 40% vs. 82%, p = 0.006, respectively). These results suggest that advanced DEL may need discrete treatment strategies.
Hiromichi Takahashi; Katsuhiro Miura; Masaru Nakagawa; Masahiko Sugitani; Yusuke Amano; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Sumiko Kobayashi; Atsuko Hojo; Yujin Kobayashi; Yukio Hirabayashi; Machiko Kusuda; Yoshihiro Hatta; Tomohiro Nakayama; Masami Takei. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy. Leukemia & Lymphoma 2016, 57, 2784 -2790.
AMA StyleHiromichi Takahashi, Katsuhiro Miura, Masaru Nakagawa, Masahiko Sugitani, Yusuke Amano, Daisuke Kurita, Masashi Sakagami, Shimon Ohtake, Yoshihito Uchino, Hitomi Kodaira, Noriyoshi Iriyama, Sumiko Kobayashi, Atsuko Hojo, Yujin Kobayashi, Yukio Hirabayashi, Machiko Kusuda, Yoshihiro Hatta, Tomohiro Nakayama, Masami Takei. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy. Leukemia & Lymphoma. 2016; 57 (12):2784-2790.
Chicago/Turabian StyleHiromichi Takahashi; Katsuhiro Miura; Masaru Nakagawa; Masahiko Sugitani; Yusuke Amano; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Sumiko Kobayashi; Atsuko Hojo; Yujin Kobayashi; Yukio Hirabayashi; Machiko Kusuda; Yoshihiro Hatta; Tomohiro Nakayama; Masami Takei. 2016. "Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy." Leukemia & Lymphoma 57, no. 12: 2784-2790.
Katsuhiro Miura; Yoshihiro Hatta; Masami Takei. Advances in Immunotherapy for Hematological Malignancies. Journal of Nihon University Medical Association 2016, 75, 167 -170.
AMA StyleKatsuhiro Miura, Yoshihiro Hatta, Masami Takei. Advances in Immunotherapy for Hematological Malignancies. Journal of Nihon University Medical Association. 2016; 75 (4):167-170.
Chicago/Turabian StyleKatsuhiro Miura; Yoshihiro Hatta; Masami Takei. 2016. "Advances in Immunotherapy for Hematological Malignancies." Journal of Nihon University Medical Association 75, no. 4: 167-170.
Highlights•PALSAR makes nucleic acid assembly by a pair of DNA probes.•PALSAR is a novel signal amplification technology for detecting nucleic acids.•Multiple species of mRNAs could be detected simultaneously and directly in a single tube by PALSAR.•For mRNA detection, there was a high correlation between PALSAR and real-time PCR. AbstractWe describe a novel technology for detecting nucleic acids: Probe Alteration Link Self-Assembly Reactions (PALSAR). PALSAR comprises DNA self-assembly of pairs of short DNA probes formed by alternate hybridization of three complementary regions in a pair of honeycomb probes (HCPs). Self-assembly occurs at designated salt concentrations and reaction temperatures and requires no enzymes. We prepared pairs of HCPs to detect mRNAs encoded by the GAPDH gene β-actin (BA) gene, CD3D gene, CD4 gene, major vault protein (MV) gene and the signalling lymphocytic activation molecule-associated protein (SAP) gene, and succeeded in quantitatively detecting these mRNAs. PALSAR could detect mRNA directly without synthesizing cDNA. Moreover, multiple mRNAs could be detected simultaneously in a single reaction tube and there was a good correlation between the results obtained PALSAR and those by real-time PCR.
Mitsugu Usui; Toshihiko Fujikawa; Masako Osawa; Chikako Hakii; Natsumi Ikumi; Takamasa Nozaki; Noboru Kitamura; Yoshihiro Hatta; Shigeyoshi Fujiwara; Masami Takei. Self-assembly formed by a short DNA probe pair: Application for highly sensitive mRNA species detection without reverse transcription. Biochemical and Biophysical Research Communications 2015, 467, 1012 -1018.
AMA StyleMitsugu Usui, Toshihiko Fujikawa, Masako Osawa, Chikako Hakii, Natsumi Ikumi, Takamasa Nozaki, Noboru Kitamura, Yoshihiro Hatta, Shigeyoshi Fujiwara, Masami Takei. Self-assembly formed by a short DNA probe pair: Application for highly sensitive mRNA species detection without reverse transcription. Biochemical and Biophysical Research Communications. 2015; 467 (4):1012-1018.
Chicago/Turabian StyleMitsugu Usui; Toshihiko Fujikawa; Masako Osawa; Chikako Hakii; Natsumi Ikumi; Takamasa Nozaki; Noboru Kitamura; Yoshihiro Hatta; Shigeyoshi Fujiwara; Masami Takei. 2015. "Self-assembly formed by a short DNA probe pair: Application for highly sensitive mRNA species detection without reverse transcription." Biochemical and Biophysical Research Communications 467, no. 4: 1012-1018.
Introduction: Rituximab is a monoclonal antibody against CD20, which has been widely used for treatment of malignant B-cell neoplasms. Although its administration is generally safe, infusion reaction (IR), a major adverse event of rituximab, occasionally deteriorates the adherence to treatment. This study extracts predicting factors for IR to identify patients who can safely receive rapid infusion of rituximab.
Akihiro Uchiike; Tatsuya Hayama; Katsuhiro Miura; Daisuke Tsutsumi; Masatoshi Hayasaka; Yoshihiro Hatta; Masami Takei; Yoshikazu Yoshida. A clinical prediction model for infusion reaction to rituximab. Annals of Oncology 2015, 26, vii80 -vii80.
AMA StyleAkihiro Uchiike, Tatsuya Hayama, Katsuhiro Miura, Daisuke Tsutsumi, Masatoshi Hayasaka, Yoshihiro Hatta, Masami Takei, Yoshikazu Yoshida. A clinical prediction model for infusion reaction to rituximab. Annals of Oncology. 2015; 26 ():vii80-vii80.
Chicago/Turabian StyleAkihiro Uchiike; Tatsuya Hayama; Katsuhiro Miura; Daisuke Tsutsumi; Masatoshi Hayasaka; Yoshihiro Hatta; Masami Takei; Yoshikazu Yoshida. 2015. "A clinical prediction model for infusion reaction to rituximab." Annals of Oncology 26, no. : vii80-vii80.
The clinical significance of concurrent expression of MYC and BCL2 protein, known as "double-expressor lymphoma" (DEL), among patients with relapsed or refractory aggressive B-cell lymphomas, remains unclear. A retrospective analysis was performed of 38 patients treated with a salvage treatment consisting of rituximab, ifosfamide, etoposide, cytarabine and dexamethasone followed by consolidative high-dose chemotherapies. A total of 17 cases (45%) were categorized as DEL using immunohistochemical assay with a cut-off value of positivity of 40% for MYC and 50% for BCL2, respectively. DEL was associated with a lower overall response rate (35% vs 71%, p = 0.0481), worse 2-year progression-free survival (9% vs 67%, p = 0.001) and overall survival (35% vs 71%, p = 0.037). This analysis suggests that DEL is common among patients with relapsed/refractory aggressive B-cell lymphomas and that such patients require novel treatment strategies.
Katsuhiro Miura; Hiromichi Takahashi; Masaru Nakagawa; Asami Izu; Masahiko Sugitani; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Yujin Kobayashi; Noriyoshi Iriyama; Sumiko Kobayashi; Satomi Kiso; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei. Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy. Leukemia & Lymphoma 2015, 57, 1 -7.
AMA StyleKatsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Asami Izu, Masahiko Sugitani, Daisuke Kurita, Masashi Sakagami, Shimon Ohtake, Yoshihito Uchino, Atsuko Hojo, Hitomi Kodaira, Mai Yagi, Yujin Kobayashi, Noriyoshi Iriyama, Sumiko Kobayashi, Satomi Kiso, Yukio Hirabayashi, Yoshihiro Hatta, Masami Takei. Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy. Leukemia & Lymphoma. 2015; 57 (6):1-7.
Chicago/Turabian StyleKatsuhiro Miura; Hiromichi Takahashi; Masaru Nakagawa; Asami Izu; Masahiko Sugitani; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Yujin Kobayashi; Noriyoshi Iriyama; Sumiko Kobayashi; Satomi Kiso; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei. 2015. "Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy." Leukemia & Lymphoma 57, no. 6: 1-7.
Noriyoshi Iriyama; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Katsuhiro Miura; Daisuke Kurita; Hitomi Kodaira; Hiromichi Takahashi; Yoshikazu Iizuka; Mitsuru Inoue; Masami Takei. Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Anticancer Research 2015, 35, 1 .
AMA StyleNoriyoshi Iriyama, Yoshihiro Hatta, Sumiko Kobayashi, Yoshihito Uchino, Katsuhiro Miura, Daisuke Kurita, Hitomi Kodaira, Hiromichi Takahashi, Yoshikazu Iizuka, Mitsuru Inoue, Masami Takei. Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Anticancer Research. 2015; 35 (10):1.
Chicago/Turabian StyleNoriyoshi Iriyama; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Katsuhiro Miura; Daisuke Kurita; Hitomi Kodaira; Hiromichi Takahashi; Yoshikazu Iizuka; Mitsuru Inoue; Masami Takei. 2015. "Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors." Anticancer Research 35, no. 10: 1.
Granulocyte colony-stimulating factor (G-CSF) promotes proliferation, survival, and differentiation of myeloid-linage leukemic cells, as well as normal hematopoietic cells. Terminal granulocytic differentiation can be induced in acute promyelocytic (APL) cell line HT93A by G-CSF and all-trans retinoic acid (ATRA). Because the detailed mechanism has never been shown, we investigated the signal transduction pathway in granulocytic differentiation by G-CSF, alone or in combination with ATRA. HT93A cell viability and growth were investigated by trypan blue exclusion assay. Cell differentiation was assessed by CD11b and CD34 expressions. Intracellular protein expressions were also evaluated by flow cytometry after fixation and permeabilization. ATRA (100 nM) induced granulocytic differentiation (upregulation of CD11b and downregulation of CD34) and the effect was potentiated by addition of G-CSF, while G-CSF alone had no effect on HT93A cells. The addition of G-CSF to ATRA had little or no effect on NB4 and THP-1 cells in comparison to ATRA alone. G-CSF receptor expression was reduced by ATRA treatment in a time-dependent manner. After 5 days’ incubation with ATRA, the expression levels of signal transducer and activator of transcription (STAT) 3, and phosphorylated STAT3 and STAT5, were significantly reduced. STAT5 was strongly activated by G-CSF stimulation in ATRA-pretreated cells in comparison to untreated cells. In contrast, STAT3 showed no response to G-CSF. Janus kinase (JAK) inhibitor ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of G-CSF, as evidenced by the levels of CD11b and CD34 expression. These results suggest G-CSF activates STAT5 through the JAK pathway in combination with ATRA, resulting in myeloid differentiation in HT93A cells. In conclusion, activation of the JAK-STAT pathway is likely essential for inducting differentiation in the APL cell line HT93A; thus, monitoring its expression and activation is important for predicting clinical efficacy and understanding the mechanisms of cytokine-dependent myelopoiesis, proliferation, and differentiation of acute myeloid leukemia.
Yoshihito Uchino; Noriyoshi Iriyama; Yoshihiro Hatta; Masami Takei. Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A. Cancer Cell International 2015, 15, 1 -11.
AMA StyleYoshihito Uchino, Noriyoshi Iriyama, Yoshihiro Hatta, Masami Takei. Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A. Cancer Cell International. 2015; 15 (1):1-11.
Chicago/Turabian StyleYoshihito Uchino; Noriyoshi Iriyama; Yoshihiro Hatta; Masami Takei. 2015. "Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A." Cancer Cell International 15, no. 1: 1-11.
Although there are several case reports of human parvovirus B19 infection in patients with hereditary spherocytosis, no systematic reviews of adult patients with hereditary spherocytosis with human parvovirus B19 infection have been published as clinical case reports. In this study, we report a case of aplastic crisis due to human parvovirus B19 infection in an adult patient with hereditary spherocytosis. A 33-year-old woman with hereditary spherocytosis and gallstones was admitted because of rapid progress in marked anemia and fever. Although empiric antibiotic therapy was prescribed, her clinical symptoms and liver function test worsened. Because the anti-human parvovirus B19 antibody and deoxyribonucleic acid levels assessed by polymerase chain reaction were positive, the patient was diagnosed with aplastic crisis due to the human parvovirus B19 infection. We collected and reviewed several case reports of patients with hereditary spherocytosis aged > 18 years with human parvovirus B19 infection between 1984 and 2010. A total of 19 reports with 22 cases [median age, 28 years (range, 18–43 range); male: female ratio, 6:16], including the present case were identified. The male-to-female ratio of 6:16 implied that younger females were predominantly affected. Although fever and abdominal symptoms were common initial symptoms, liver dysfunction or skin eruptions were less commonly documented. Anti-human parvovirus B19 antibody or deoxyribonucleic acid levels assessed by polymerase chain reaction was commonly used to diagnose human parvovirus B19 infection and may be useful to distinguish human parvovirus B19 infection from other abdominal infection in patients with hereditary spherocytosis.
Yujin Kobayashi; Yoshihiro Hatta; Yusaku Ishiwatari; Hitoshi Kanno; Masami Takei. Human parvovirus B19-induced aplastic crisis in an adult patient with hereditary spherocytosis: a case report and review of the literature. BMC Research Notes 2014, 7, 137 -137.
AMA StyleYujin Kobayashi, Yoshihiro Hatta, Yusaku Ishiwatari, Hitoshi Kanno, Masami Takei. Human parvovirus B19-induced aplastic crisis in an adult patient with hereditary spherocytosis: a case report and review of the literature. BMC Research Notes. 2014; 7 (1):137-137.
Chicago/Turabian StyleYujin Kobayashi; Yoshihiro Hatta; Yusaku Ishiwatari; Hitoshi Kanno; Masami Takei. 2014. "Human parvovirus B19-induced aplastic crisis in an adult patient with hereditary spherocytosis: a case report and review of the literature." BMC Research Notes 7, no. 1: 137-137.
There has been significant progress in cytokine-blocking therapy for treatment of rheumatoid arthritis (RA) However, inhibition of cytokines involved in immune defense raises severe side effects. The cost of cytokine-blocking treatment is another major issue. Why are levels of inflammatory cytokines increased in RA patients? We have a large amount of circumstantial and direct evidence for the presence of Epstein-Barr virus (EBV) in RA synovial cells. Here, we provide an overview of the implications for novel approaches to therapy for RA patients, based on the most recent available evidences of anti-viral agents.
Shigemasa Sawada; Masami Takei; Hirotake Inomata; Takamasa Nozaki; Hidetaka Shiraiwa. What is after cytokine-blocking therapy, a novel therapeutic target — Synovial Epstein-Barr virus for rheumatoid arthritis. Autoimmunity Reviews 2007, 6, 126 -130.
AMA StyleShigemasa Sawada, Masami Takei, Hirotake Inomata, Takamasa Nozaki, Hidetaka Shiraiwa. What is after cytokine-blocking therapy, a novel therapeutic target — Synovial Epstein-Barr virus for rheumatoid arthritis. Autoimmunity Reviews. 2007; 6 (3):126-130.
Chicago/Turabian StyleShigemasa Sawada; Masami Takei; Hirotake Inomata; Takamasa Nozaki; Hidetaka Shiraiwa. 2007. "What is after cytokine-blocking therapy, a novel therapeutic target — Synovial Epstein-Barr virus for rheumatoid arthritis." Autoimmunity Reviews 6, no. 3: 126-130.